LEXG-Lexicon Genetics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics

LXRX 1.250

-12.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (93)	9/10/2001 5:11:19 PM
From: nigel bates	Read Replies (1) of 254

Genomeweb article where Atugen compares knockout unfavourably with antisense - genomeweb.com ...Atugen said that unlike knockout technology, its “knockdown” methodology allows researchers to reduce expression of specific genes in designated cells. The company added that this provides a highly selective and low toxicity way of evaluating gene expression. Plus, Atugen said that its technology can be used after the genes have been developed in utero, reducing the number of false positives that occur in knockout systems....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next